Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation to RemeGen's Telitacicept as a Treatment for Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"RemeGen"},{"company":"InnoCare Pharma","sponsor":"WuXi STA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Orelabrutinib Included in Priority Review by NMPA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"InnoCare Pharma"},{"company":"InnoCare Pharma","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$937.5 million","upfrontCash":"$125.0 million","newsHeadline":"Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib For the Treatment of Multiple Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"InnoCare Pharma"},{"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Pharma Gets China NMPA Nod to Begin Phase II Trial of Orelabrutinib","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"InnoCare Pharma"},{"company":"Lynk Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynk Pharmaceuticals Announced First Patient Dosed in Phase II Clinical Study of LNK01001","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Lynk Pharmaceuticals"},{"company":"Lynk Pharmaceuticals","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lynk Pharmaceuticals and Simcere Announced Strategic Commercialization Partnership upon Novel JAK1 Inhibitor LNK01001","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Lynk Pharmaceuticals"},{"company":"Inmagene Biopharmaceuticals","sponsor":"Affibody","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inmagene and Affibody Announce IND Clearance for Izokibep (IMG-020) For the Treatment of Ankylosing Spondylitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Inmagene Biopharmaceuticals"},{"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Latest Data of InnoCare\u2019s Robust Oncology Pipelines Presented at the 2022 ASCO Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"InnoCare Pharma"}]

InnoCare Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2022 ASCO Annual Meeting

Details:

ICP-022 (orelabrutinib) is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases. The plasma exposure of orelabrutinib (AUC and Cmax) was proportionally increased with doses.

Lead Product(s): Orelabrutinib

Therapeutic Area: Immunology Product Name: ICP-022

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 06, 2022

ASK
US

Upload
your Pipeline Activity

Lynk Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Lynk Pharmaceuticals and Simcere Announced Strategic Commercialization Partnership upon Novel JAK1 Inhibitor LNK01001

Details:

Under the terms of the agreement, Lynk Pharmaceuticals is responsible for the development of the product. Simcere will obtain the exclusive rights to market LNK01001 for the indications of rheumatoid arthritis and ankylosing spondylitis in China.

Lead Product(s): LNK01001

Therapeutic Area: Immunology Product Name: LNK01001

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Jiangsu Simcere Pharmaceutical

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership March 18, 2022

ASK
US

Upload
your Pipeline Activity

Lynk Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Lynk Pharmaceuticals Announced First Patient Dosed in Phase II Clinical Study of LNK01001

Details:

First dose has been administered of LNK01001, a selective kinase inhibitor for the treatment of autoimmune diseases in subjects with rheumatoid arthritis. The results of Phase I clinical research have shown favorable safety profile and tolerability.

Lead Product(s): LNK01001

Therapeutic Area: Immunology Product Name: LNK01001

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 01, 2021

ASK
US

Upload
your Pipeline Activity

InnoCare Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

InnoCare Pharma Gets China NMPA Nod to Begin Phase II Trial of Orelabrutinib

Details:

Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.

Lead Product(s): Orelabrutinib

Therapeutic Area: Immunology Product Name: ICP-022

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 11, 2021

ASK
US

Upload
your Pipeline Activity

InnoCare Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib For the Treatment of Multiple Sclerosis

Details:

Biogen will have exclusive rights to orelabrutinib in the field of MS worldwide and certain autoimmune diseases outside of China, while InnoCare will retain exclusive worldwide rights to orelabrutinib in the field of oncology and certain autoimmune diseases in China.

Lead Product(s): Orelabrutinib

Therapeutic Area: Immunology Product Name: ICP-022

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Biogen

Deal Size: $937.5 million Upfront Cash: $125.0 million

Deal Type: Collaboration July 12, 2021

ASK
US

Upload
your Pipeline Activity

Inmagene Biopharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Inmagene and Affibody Announce IND Clearance for Izokibep (IMG-020) For the Treatment of Ankylosing Spondylitis

Details:

IMG-020, Inmagene's most advanced drug candidate, is in global clinical trials for multiple indications. The trial will evaluate the efficacy, safety and tolerability of three different dosage regimens of izokibep as compared to placebo.

Lead Product(s): Izokibep

Therapeutic Area: Immunology Product Name: IMG-020

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Affibody

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 10, 2021

ASK
US

Upload
your Pipeline Activity

InnoCare Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

InnoCare Orelabrutinib Included in Priority Review by NMPA

Details:

The National Drug Administration of China (NMPA) Drug Evaluation Center (CDE) has prioritized the new drug application (NDA) for Orelabrutinib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL).

Lead Product(s): Orelabrutinib

Therapeutic Area: Immunology Product Name: ICP-022

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: WuXi STA

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2021

ASK
US

Upload
your Pipeline Activity

RemeGen

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

FDA Grants Fast Track Designation to RemeGen's Telitacicept as a Treatment for Systemic Lupus Erythematosus

Details:

US FDA granted Fast Track designation for RC18, for the treatment of systemic lupus erythematosus (SLE). RC18 shows statistically significant improvement for patients at multiple doses.

Lead Product(s): Telitacicept

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 15, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY